Orchid Cellmark news from FierceBiotech
NewsC&L: Somnus names executive team
Gary Cupit, PharmD, has been named CEO of Somnus Therapeutics. The rest of the executive team: Mary Osbakken, MD, PhD, chief medical officer; Christine Blumhardt, PharmD, chief regulatory officer; Read more...
| Press ReleasesPRESS RELEASE: Orchid Cellmark to Buy ReliaGene for $8.6 Million Orchid Cellmark to Buy ReliaGene for $8.6 Million PRINCETON, N.J., Oct. 2w -- Orchid Cellmark, , a leading worldwide provider of identity DNA testing services, today announced that it has signed a Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets